Pfizer Inc. (PFE) announced the U.S. Federal Trade Commission has terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to Pfizer's pending acquisition of Hospira (HSP). The FTC's clearance is contingent upon Pfizer's commitment to divest four U.S. sterile injectable assets, including Acetylcysteine, Clindamycin, Voriconazole and Melphalan.
Pfizer also announced that Brazil's Superintendency-General of CADE has published its unconditional clearance decision.
Pfizer expects to close the transaction in early September.
For comments and feedback contact: editorial@rttnews.com
Business News